 |
| Alex Kelly |
Precision BioSciences, Inc., a clinical-stage biotechnology company, has appointed Alex Kelly chief corporate affairs officer.
Kelly comes to the company from Allergan, where he was executive vice president, corporate affairs and chief communications officer, as well as president of The Allergan Foundation. In those roles, he developed internal and external messaging and supported Allergan’s recent merger with AbbVie.
Kelly has also served as senior VP, chief integration officer at Actavis and senior VP, chief communications officer, public affairs and investor relations at Forest Labs.
In his new role, he will join the senior leadership team and oversee all investor relations and corporate communications. "Alex brings valuable and meaningful experience leading corporate affairs for some of the most successful healthcare companies in the industry,” said Precision CEO Matt Kane.
Jim Weiss, founder & chairman of Real Chemistry, has joined the board of ICR Inc. as it steps up its healthcare capital markets offering.
Ruder Finn has hired Kelly Yoder, who spent a dozen years at Weber Shandwick rising to North America health lead, as managing director, global head of health & life sciences.
ICR has named John Capodanno head of US healthcare corporate communications and Matthew Willey managing director in its medical technology and diagnostics practice. 
April is National Minority Health Month, spotlighting the urgency to improve health outcomes in communities of color.
In a recent conversation about the evolving media landscape, Doug Simon, CEO of D S Simon Media, spoke with Campbell O’Connor, Group Director, Media & Engagement at Real Chemistry, about how AI is influencing media relations and healthcare communications.
